Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents

Ceylan, Mehmet Fatih; Erdogan, Betül; Hesapçıoğlu, Selma Tural; Çöp, Esra

doi:10.1007/s40261-017-0555-7

Cited by 21 publications

(19 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there are no studies looking at LAIAs in youth with ASD specifically, outside of a single case report (Kowalski et al, 2011), work in other psychiatric disorders such as schizophrenia suggest that they are safe and well tolerated, with similar side effect profiles to oral medications. In addition, use of LAIAs is associated with improved adherence and lower overall treatment costs (Ceylan et al, 2017;Lytle et al, 2017). Future description of LAIA use in the context of ASD is needed to inform prescribing practice for patients where oral formulations may be refused or contraindicated.…”

Section: Long Acting Injectable Antipsychoticsmentioning

confidence: 99%

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

Henneberry

Lamy

Dominick

et al. 2021

J Autism Dev Disord

View full text Add to dashboard Cite

Recent decades have been marked by a wave drug treatment research in autism spectrum disorder (ASD). This work has resulted in improved ability to treat commonly occurring behavioral challenges associated with ASD including most prominently irritability marked by aggression, self-injurious behavior, and severe tantrums. While treatment of interfering behavior has progressed in our field, there remain several areas of unmet medical need including most prominently a lack of any approved drug therapies for the core, defining symptoms of autism. We outline the progress to date in the field of autism drug treatment while taking a future look forward into how decades of work can inform better future steps in this field.

show abstract

Section: Long Acting Injectable Antipsychoticsmentioning

confidence: 99%

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

Henneberry

Lamy

Dominick

et al. 2021

J Autism Dev Disord

View full text Add to dashboard Cite

show abstract

“…For example, patients prescribed SGA drugs often show greater improvement in negative and cognitive symptoms, higher functional capacity, and have better quality of life with lower risks of extrapyramidal side effects (EPS) and tardive dyskinesia (TD) . However, some concerns exist about treatment with risperidone as it may induce side effects such as hyperprolactinaemia , hyperuricaemia , weight gain and dyslipidaemia . Additionally, risperidone could increase the risk of type 2 diabetes .…”

mentioning

confidence: 99%

Pharmacogenetics of Risperidone‐Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder

Sukasem

Vanwong

Srisawasdi

et al. 2018

Basic Clin Pharma Tox

View full text Add to dashboard Cite

The purpose of this study was to explore the association of genetic polymorphism of genes related to pharmacokinetics or pharmacodynamics with insulin resistance in children and adolescents with autism spectrum disorder (ASD) and treated with risperidone. All 89 subjects underwent measurement of fasting blood glucose and insulin levels, body-weight and height. Genotyping was performed by TaqMan real-time polymerase chain reaction (PCR) (pharmacokinetics genes: cytochrome P450 2D6 (CYP2D6) *4 (rs3892097), *5 (gene deletion), *10 (rs1065852) and *41 (rs28371725), ATP-binding cassette transporter B1 (ABCB1) 2677 G>T/A (rs2032582) and 3435C>T (rs1045642) and pharmacodynamics genes: dopamine receptor D2 (DRD2) Tag-SNP (C>T) (rs4436578), DRD2 Tag1A (C>T) (rs1800497), leptin gene (LEP) -2548G>A (rs7799039), ghrelin gene (GHRL) -604G>A (rs27647) and brain-derived neurotrophic factor (BDNF) 196G>A (rs6265)). Drug levels were analysed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The results revealed that 5 (5.62%) patients presented with hyperglycaemia. Insulin resistance was detected in 15 (16.85%) patients. Insulin resistance was associated with LEP 2548 G>A and BDNF 196 G>A polymorphism (p = 0.051 and p = 0.03). There was no association of pharmacokinetic gene polymorphisms (CYP2D6 and ABCB1) and risperidone levels with insulin resistance. Multiple regression analysis indicated that BDNF 196 G>A polymorphism was significantly associated with insulin resistance (p = 0.025). This finding suggested that BDNF 196 G>A polymorphism may be a genetic marker for predicting insulin resistance before initiating treatment in patients treated with risperidone. Because of the small sample size, further studies are needed to confirm these results.

show abstract

“…Moreover, paliperidone has less of an effect on liver function, which is much more easily accepted by children and adolescents, who are more sensitive to drug side effects [39,40]. Risperidone was more commonly used in patients with COS. An open controlled study abroad showed that risperidone can significantly improve the positive and negative symptoms of adolescent schizophrenia patients and cause less extrapyramidal reactions than traditional antipsychotics [41,42]. The frequencies of use of aripiprazole and clozapine were not significantly different in the AOS and COS groups.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: a retrospective study

et al. 2021

View full text Add to dashboard Cite

Background There is limited evidence on the use of antipsychotics in patients with early-onset schizophrenia, which lags significantly behind the studies on adult patients’ medication and has a large disparity from actual clinical needs. Hence, this study aims to analyse the status of the drug use and its changes for patients with early-onset schizophrenia in our ward and to provide references on clinical medications for children and adolescents with schizophrenia. Methods The distribution of antipsychotics on the day of discharge and their changes over time were retrospectively analysed in our inpatient department from March 2012 to July 2019. Descriptive statistical methods and χ2 tests were carried out. Results A total of 746 inpatients with early-onset schizophrenia were included. Among them, 99.3% of patients were prescribed atypical antipsychotic drugs, with 5.5% of patients prescribed typical antipsychotic drugs. The top five most commonly used antipsychotics were aripiprazole, olanzapine, risperidone, paliperidone and clozapine. Olanzapine and risperidone were used more frequently in men (P < 0.01), whereas aripiprazole was used less frequently (P < 0.01). Olanzapine and paliperidone were used more frequently in patients with adolescent-onset schizophrenia (AOS) (P < 0.05), and risperidone was used more frequently in patients with child-onset schizophrenia (COS) (P < 0.01). Multiple antipsychotics during hospitalization were prescribed in 23.1% of patients. The combination of aripiprazole and olanzapine was the most common in the AOS group, and the combination of risperidone and clozapine was the most common in the COS group. Before and after approval by the competent Chinese authorities, the use of paliperidone and aripiprazole tended to be stable. Conclusion Atypical antipsychotics have been increasingly valued and used clinically. The consideration of medications for patients with early-onset schizophrenia needs to include factors such as age, sex, and severity of illness, metabolism and cognitive function at baseline.

show abstract

Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents

Cited by 21 publications

References 32 publications

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

Pharmacogenetics of Risperidone‐Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder

Analysis of the status of drug treatment in 746 inpatients with early-onset schizophrenia in China: a retrospective study

Contact Info

Product

Resources

About